Table 3.
Risk of Meningioma in Patients Whose Initial Diagnosis Was Cancer and Were Treated by Radiotherapy, by Age and GH Treatment Variables
| n | SIR (95% CI) | |
|---|---|---|
| Age started GH treatment, y | ||
| 0–4 | 1 | 1401.5 (197.4, 9949.0)a |
| 5–9 | 9 | 782.4 (407.1, 1503.7)b |
| 10–14 | 19 | 644.7 (411.2, 1010.7)b |
| 15-19 | 1 | 258.1 (36.4, 1832.1)a |
| P trend | 0.21 | |
| Time since started GH treatment, y | ||
| 0–4 | 2 | 338.0 (84.5, 1351.4)b |
| 5–9 | 2 | 197.5 (49.4, 789.5)b |
| 10–14 | 14 | 1130.7 (669.7, 1909.2)b |
| 15–19 | 10 | 857.0 (461.1, 1592.8)b |
| ≥20 | 2 | 365.8 (91.5, 1462.5)b |
| P trend | 0.26 | |
| Attained age, y | ||
| 0–9 | 0 | 0.0 (0.0, 12,296.3) |
| 10–19 | 6 | 487.2 (218.9, 1084.3)b |
| 20–29 | 21 | 863.5 (563.0, 1324.4)b |
| ≥30 | 3 | 346.7 (111.8, 1074.8)b |
| P trend | 0.95 | |
| Duration of GH treatment, y | ||
| <3 | 8 | 547.5 (273.8, 1094.7)b |
| 3–5 | 11 | 587.3 (325.3, 1060.5)b |
| ≥6 | 11 | 998.9 (553.2, 1803.8)b |
| P trend | 0.19 | |
| Mean GH dose, µg/kg/d | ||
| <20 | 7 | 635.1 (302.8, 1332.2)b |
| 20–29 | 17 | 805.4 (500.7, 1295.6)b |
| 30–39 | 3 | 425.1 (137.1, 1318.1)b |
| ≥40 | 1 | 1297.5 (182.8, 9210.9)a |
| P trend | 0.92 | |
| Cumulative GH dose, mg/kg | ||
| <25 | 8 | 511.9 (256.0, 1023.7)b |
| 25–49 | 10 | 601.3 (323.6, 1117.6)b |
| 50–99 | 11 | 1286.0 (712.2, 2322.1)b |
| ≥100 | 0 | 0.0 (0.0, 4098.8) |
| P trend | 0.13 | |
| Total | 30 | 658.4 (460.4, 941.7)b |
a
P < 0.01.
b
P < 0.001.
c
P < 0.05.